Skip to main content
. Author manuscript; available in PMC: 2022 Nov 28.
Published in final edited form as: J Invest Dermatol. 2021 Dec 7;142(7):1882–1892.e5. doi: 10.1016/j.jid.2021.11.027

Figure 4. Inhibition of GSK-3 upregulates NUMB in metastatic melanoma cell lines.

Figure 4.

(a) Immunoblot analysis showing the expression of NUMB, active b-Cat, and total b-Cat in WM1799 and WM3451 melanoma cell lines treated with GSK-3i IX. The 0 h–treated samples refer to the cells incubated for 24 h in the media without GSK-3i IX. Blotting for b-actin serves as a loading control. The relative intensities of the immunoblot bands were quantified. (b) Immunofluorescent staining showing the expression of NUMB and active b-catenin after treatment with GSK-3i IX in WM1799 and WM3451 melanoma cell lines. Bar = 100 mm. b- Cat, b-catenin; Act., active; GSK-3, glycogen synthase kinase-3; GSK-3i, glycogen synthase kinase-3 inhibitor; h, hour.